Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750988 | 0.82 | CA1 (0.36) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL10476636 | 0.79 | CYP2A6 (0.39) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL5051704 | 0.79 | ALDH1A1 (0.39) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL7408803 | 0.79 | ALDH1A1 (0.39) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL28656149 | 0.76 | CYP1A2 (0.44) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL16289785 | 0.76 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL21858086 | 0.75 | APP (0.44) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL21858026 | 0.73 | CHAT (0.45) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL27536223 | 0.73 | MDM4 (0.43) | ALDH1A1HSD17B10TDP1KDM4EMAPT | |
| SCHEMBL27901223 | 0.73 | CHEK1 (0.33) | ALDH1A1CYP2A6KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | claimed |
| CN-115215763-A | Mass spectrum matrix material and preparation method thereof | 闽江学院 | 2022-10-21 | — | — | CN | claimed |
| CN-108889127-B | Nano-scale filter membrane and preparation method and application thereof | 安徽诺乐知识产权服务有限公司 | 2021-08-31 | — | — | CN | claimed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | claimed |
| CN-113019156-A | Composite nanofiltration membrane | 安徽原上草节能环保科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-113019155-A | Composite microfiltration membrane | 安徽原上草节能环保科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-108905626-B | Composite ultrafiltration membrane and preparation method and application thereof | 北京亿家清泉环保科技有限公司 | 2021-06-08 | — | — | CN | claimed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | claimed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| CN-110612299-A | Pyrimidine derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | claimed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| CN-102190797-A | Quick synthesizing method of triazinyl covalent bond organic framework material with nano pores and application thereof | UNIV ANHUI | 2011-09-21 | — | — | CN | claimed |
| CN-101213194-A | Indazoles useful in treating cardiovascular diseases | WYETH CORP (US) | 2008-07-02 | — | — | CN | claimed |
| EP-1805179-A2 | PREPARATION OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | Brystol-Myers Squibb Company (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006135425-A2 | PREPARATION OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | claimed |
| US-20060069085-A1 | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-30 | — | — | US | claimed |
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1032436-A | The method of biological production of amides | HIDEAKI YAMADA (JP) | 1989-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CA1 4747/4885CA2 3989/4885ALDH1A1 468/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CA1 4747/4885CA2 3989/4885ALDH1A1 468/4885 |
| US-20060069085-A1 | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | F2, TFPI, TFPI2 | CA1 3664/4885CA2 3089/4885ALDH1A1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.